No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1992 and headquartered in Shenzhen, China, Shenzhen Kangtai Biological Products Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of a diverse array of human vaccines across the Chinese market. The company's extensive portfolio includes essential immunizations such as the SARS-COV-2 vaccine, recombinant hepatitis B vaccine, and various pneumococcal disease vaccines (including 13-valent conjugate and 23-valent polysaccharide types). Its offerings also encompass combined vaccines like diphtheria, tetanus, acellular pertussis, and haemophilus influenzae type b, in addition to specific haemophilus influenzae type b conjugate, measles and rubella live attenuated, rabies, and inactivated poliomyelitis vaccines. Internationally, the company has partnered with YTB and Yong Tai Berhad to develop and commercialize a Covid-19 inactivated vaccine specifically for Malaysia.
www.biokangtai.comNo one on the platform currently holds 300601.SZ.
No tracked institution reports a position in 300601.SZ as of their last filing.
No one on the platform has traded 300601.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.5% | — | — | — | ||
| Rev. Growth % | 0.8% | 3.4% | ||||
| Profit Margin % | 2.6% | 13.1% | 18.1% | |||
| Free Cash Flow Margin % | 11.4% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.7B | -0.3% | $0.11 | $0.10–$0.11 | — | 2 |
| 2027 | $2.9B | +9.2% | $0.20 | $0.19–$0.22 | — | 2 |
| 2028 | $3.2B | +9.5% | $0.28 | $0.15–$0.44 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-22 | $0.02 | $0.01 | -26.0% |
| 2026-04-21 | $0.07 | $0.02 | -71.5% |
| 2026-04-21 | $0.05 | $0.01 | -84.3% |
| 2025-10-27 | $0.07 | $0.01 | -84.4% |
| 2025-08-21 | $0.06 | $0.01 | -76.3% |
| 2025-04-21 | $0.02 | $0.02 | +6.0% |
| 2025-04-20 | $0.08 | $-0.10 | -219.6% |
| 2024-10-25 | $0.20 | $0.16 | -20.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300601.SZShenzhen Kangtai Biological Products Co., Ltd. | $11.73 | +0.60% | $13.1B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.46 | +0.40% | $26.0B | — |
| 002317.SZGuangdong Zhongsheng Pharmaceutical Co., Ltd. | $24.79 | -0.04% | $21.1B | — |
| 002755.SZBeijing Aosaikang Pharmaceutical Co., Ltd. | $11.29 | +0.27% | $10.5B | — |
| 300142.SZWalvax Biotechnology Co., Ltd. |
| $13.05 |
| +0.31% |
| $20.9B |
| — |
| 300199.SZHybio Pharmaceutical Co., Ltd. | $23.27 | -1.36% | $20.6B | — |
| 300436.SZFujian Cosunter Pharmaceutical Co., Ltd. | $85.27 | +0.46% | $13.6B | — |
Source: Financial Modeling Prep · peers by sector/industry